Small bowel lymphoma
- 1 January 2003
- journal article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Gastroenterology
- Vol. 6 (1), 27-34
- https://doi.org/10.1007/s11938-003-0030-9
Abstract
Treatment of small bowel lymphoma requires the expertise of medical and surgical subspecialists. The two most important factors that determine the optimal treatment are histology and staging of small bowel lymphoma. Other factors that may affect treatment include age, multiple areas of involvement, tumor size, and perforation. At present, the best treatment for gastrointestinal lymphoma (stage IE disease) is limited resection of the tumor, followed by postoperative radiotherapy. The cure rate is approximately 75% for stage IE patients, even for those with aggressive histologic types. Chemotherapy is reserved for advanced-staged tumors. In patients with regional nodal involvement or extranodal involvement confined to one side of the diaphragm (pathologic stage IIE disease), chemotherapy should be combined with radiation therapy. The best chemotherapy regimen depends on the histology of the tumor. For diffuse large B-cell lymphoma, the most frequently diagnosed subtype of non-Hodgkin’s lymphoma (NHL), the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) is still the gold standard. Clinical trials have been conducted evaluating the new monoclonal antibody rituximab, along with the CHOP regimen for primary NHL. Results have been promising. The use of rituximab in the treatment of extranodal lymphoma is still being evaluated. Low-grade lymphomas have a more indolent course and do not respond as well to combination chemotherapy agents as the high-grade tumors. Fludarabine alone or in combination with cyclophosphamide is effective as a first-line agent for patients with low-grade NHL. It has also been used to treat relapsed or refractory low-grade NHL. Some promising results have been reported using the chemoimmunotherapy agent rituximab alone or in combination with fludarabine for the treatment of low-grade NHL. However, clinical trials are still needed. In patients with nodal involvement on both sides of the diaphragm or other extranodal involvement such as bone marrow or liver (pathologic stages IIIE and IVE), the disease is managed primarily with combination chemotherapy. Radiation therapy is reserved for treatment of initially bulky tumor sites, treatment of residual disease following chemotherapy, or serious local problems. The disease can be controlled in 25% to 40% of patients with stage IIIE or IVE disease. As with stage IIE disease, the optimal chemotherapy regimen depends on the histologic subtype of NHL.Keywords
This publication has 11 references indexed in Scilit:
- Immunochemotherapy in indolent non-Hodgkin's lymphomaSeminars in Oncology, 2002
- Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphomaSeminars in Oncology, 2002
- Rituximab in combination with CHOP or fludarabine in low-grade lymphomaSeminars in Oncology, 2002
- Non-Hodgkins Lymphoma: Review of Conventional TreatmentsCurrent Pharmaceutical Biotechnology, 2001
- Small Intestinal NeoplasmsJournal of Clinical Gastroenterology, 2001
- Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphomaBlood, 2000
- Primary Lymphoma of the Small Intestine A. Clinicopathological Study of 119 CasesThe American Journal of Surgical Pathology, 1993
- HTLV-I-associated lymphoma involving the entire alimentary tract and presenting with an acquired immune deficiencyAmerican Journal Of Medicine, 1987
- Malignant Lymphoma of the Small Bowel Associated with Diffuse Nodular Lymphoid HyperplasiaThe New England Journal of Medicine, 1985
- Immunoblastic lymphoma of small intestine complicating late-onset immunodeficiencyCancer, 1982